Reported about 1 year ago
A key Alzheimer's drug from Eli Lilly received favorable feedback from FDA health advisers, paving the way for its anticipated approval for individuals with mild dementia caused by Alzheimer's. The drug, donanemab, demonstrated efficacy in slowing cognitive decline, although concerns were raised about potential side effects, including brain swelling and bleeding. If approved, donanemab would become the second Alzheimer's drug in the U.S. proven to slow memory issues associated with the disease.
Source: YAHOO